Literature DB >> 14694105

Expansion of a unique region in the Marek's disease virus genome occurs concomitantly with attenuation but is not sufficient to cause attenuation.

R F Silva1, S M Reddy, B Lupiani.   

Abstract

Pathogenic Marek's disease viruses (MDVs) have two head-to-tail copies of a 132-bp repeat. As MDV is serially passaged in cell culture, the virus becomes attenuated and the number of copies of the 132-bp repeat increases from 2 to often more than 20 copies. To determine the role of the repeats in attenuation, we used five overlapping cosmid clones that spanned the MDV genome to reconstitute infectious virus (rMd5). By mutating the appropriate cosmids, we generated clones of infectious MDVs that contained zero copies of the 132-bp repeats, rMd5(Delta132); nine copies of the 132-bp repeats, rMd5(9-132); and nine copies of the 132-bp repeats inserted in the reverse orientation, rMd5(rev9-132). After two passages in cell culture, wild-type Md5, rMd5, and rMd5(Delta132) were stable. However, rMd5(9-132) and rMd5(rev9-132) contained a population of viruses that contained from 3 to over 20 copies of the repeats. A major 1.8-kb mRNA, containing two copies of the 132-bp repeat, was present in wild-type Md5 and rMd5 but was not present in rMd5(Delta132), rMd5(9-132), rMd5(rev9-132), or an attenuated MDV. Instead, the RNAs transcribed from the 132-bp repeat region in rMd5(9-132) and rMd5(rev9-132) closely resembled the pattern of RNAs transcribed in attenuated MDVs. When inoculated into susceptible day-old chicks, all viruses produced various lesions. Thus, expansion of the number of copies of 132-bp repeats, which accompanies attenuation, is not sufficient in itself to attenuate pathogenic MDVs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694105      PMCID: PMC368850          DOI: 10.1128/jvi.78.2.733-740.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

Review 1.  The genomic structure of Marek's disease virus.

Authors:  R F Silva; L F Lee; G F Kutish
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  The genome of a very virulent Marek's disease virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Comparative studies on Marek's disease virus and herpesvirus of turkey DNAs.

Authors:  K Hirai; K Ikuta; S Kato
Journal:  J Gen Virol       Date:  1979-10       Impact factor: 3.891

4.  Cis-acting elements in the lytic origin of DNA replication of Marek's disease virus type 1.

Authors:  A Katsumata; A Iwata; S Ueda
Journal:  J Gen Virol       Date:  1998-12       Impact factor: 3.891

5.  Four distinct neurologic syndromes in Marek's disease: effect of viral strain and pathotype.

Authors:  I M Gimeno; R L Witter; W M Reed
Journal:  Avian Dis       Date:  1999 Oct-Dec       Impact factor: 1.577

6.  Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials.

Authors:  B H Rispens; H van Vloten; N Mastenbroek; H J Maas; K A Schat
Journal:  Avian Dis       Date:  1972-04       Impact factor: 1.577

7.  Loss of Marek's disease virus tumorigenicity is associated with truncation of RNAs transcribed within BamHI-H.

Authors:  G Bradley; G Lancz; A Tanaka; M Nonoyama
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Cloning, sequencing, and functional analysis of a Marek's disease virus origin of DNA replication.

Authors:  H S Camp; P M Coussens; R F Silva
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Status of Marek's disease virus in established lymphoma cell lines: herpesvirus integration is common.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Most virus-specific polypeptides in cells productively infected with Marek's disease virus or herpesvirus of turkeys possess cross-reactive determinants.

Authors:  K Ikuta; S Ueda; S Kato; K Hirai
Journal:  J Gen Virol       Date:  1983-04       Impact factor: 3.891

View more
  12 in total

1.  Marek's disease virus unique genes pp38 and pp24 are essential for transactivating the bi-directional promoters for the 1.8 kb mRNA transcripts.

Authors:  Jiabo Ding; Zhizhong Cui; Lucy F Lee
Journal:  Virus Genes       Date:  2007-07-06       Impact factor: 2.332

2.  Artificially inserting a reticuloendotheliosis virus long terminal repeat into a bacterial artificial chromosome clone of Marek's disease virus (MDV) alters expression of nearby MDV genes.

Authors:  Taejoong Kim; Jody Mays; Aly Fadly; Robert F Silva
Journal:  Virus Genes       Date:  2011-02-22       Impact factor: 2.332

3.  Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder; Venugopal K Nair; Karel A Schat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  Oncogenic Marek's disease viruses lacking the 132 base pair repeats can still be attenuated by serial in vitro cell culture passages.

Authors:  R F Silva; Isabel Gimeno
Journal:  Virus Genes       Date:  2006-08-22       Impact factor: 2.332

5.  The role of pp38 in regulation of Marek's disease virus bi-directional promoter between pp38 and 1.8-kb mRNA.

Authors:  Jiabo Ding; Zhizhong Cui; Lucy F Lee; Xiaoping Cui; Sanjay M Reddy
Journal:  Virus Genes       Date:  2006-04       Impact factor: 2.332

6.  Role of Marek's Disease Virus (MDV)-Encoded US3 Serine/Threonine Protein Kinase in Regulating MDV Meq and Cellular CREB Phosphorylation.

Authors:  Yifei Liao; Blanca Lupiani; Kanika Bajwa; Owais A Khan; Yoshihiro Izumiya; Sanjay M Reddy
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

7.  Sequence determination of a mildly virulent strain (CU-2) of Gallid herpesvirus type 2 using 454 pyrosequencing.

Authors:  Stephen J Spatz; Cary A Rue
Journal:  Virus Genes       Date:  2008-03-20       Impact factor: 2.332

8.  Dynamic equilibrium of Marek's disease genomes during in vitro serial passage.

Authors:  Stephen J Spatz; Jeremy D Volkening; Isabel M Gimeno; Mohammad Heidari; Richard L Witter
Journal:  Virus Genes       Date:  2012-08-26       Impact factor: 2.332

9.  Deletion of the Marek's disease virus UL41 gene (vhs) has no measurable effect on latency or pathogenesis.

Authors:  Isabel Gimeno; Robert F Silva
Journal:  Virus Genes       Date:  2008-03-01       Impact factor: 2.332

10.  Characterizing the molecular basis of attenuation of Marek's disease virus via in vitro serial passage identifies de novo mutations in the helicase-primase subunit gene UL5 and other candidates associated with reduced virulence.

Authors:  Evin Hildebrandt; John R Dunn; Sudeep Perumbakkam; Masahiro Niikura; Hans H Cheng
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.